Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Trends in Cancer Screening-United States, 1987 and 1992

March 1, 1996
Publication
Article
OncologyONCOLOGY Vol 10 No 3
Volume 10
Issue 3

Screening methods and programs are critical strategies for the early detection and timely treatment of some cancers. Established methods for early detection of cancer include mammography, clinical breast examination (CBE), the Papanicolaou (Pap) test, proctosigmoidoscopy, fecal occult blood test (FOBT), and digital rectal examination (DRE). To examine changes in the reported use of selected cancer screening tests, the National Cancer Institute analyzed data from CDC's National Health Interview Survey (NHIS) for 1987 and 1992 to calculate rates of use and compared these rates with the national health objectives for the year 2000. This analysis suggests that, although the use of these tests increased, substantial progress is needed to meet the objectives.

Screening methods and programs are critical strategies for theearly detection and timely treatment of some cancers. Establishedmethods for early detection of cancer include mammography, clinicalbreast examination (CBE), the Papanicolaou (Pap) test, proctosigmoidoscopy,fecal occult blood test (FOBT), and digital rectal examination(DRE). To examine changes in the reported use of selected cancerscreening tests, the National Cancer Institute analyzed data fromCDC's National Health Interview Survey (NHIS) for 1987 and 1992to calculate rates of use and compared these rates with the nationalhealth objectives for the year 2000. This analysis suggests that,although the use of these tests increased, substantial progressis needed to meet the objectives.

The NHIS is a continuing nationwide household survey that collectsinformation from a representative sample of the US civilian, noninstitutionalized population age equal to or more than 18 years.The overall response rate for the 1987 and 1992 surveys was 95.3%(N = 122,859) and 95.7% (N = 128,412), respectively. In 1987 and1992, questions were included to determine respondents' knowledgeand practices regarding cancer screening. Respondents were askedwhether they had ever had a Pap test, CBE, mammography, DRE, FOBT,or proctosigmoidoscopy. Respondents who answered "yes"to any of the questions were asked when their most recent testhad been performed. Screening tests were defined as tests performedfor any reason other than as the result of a health problem.

For CBE, mammography, DRE, and FOBT, screening was consideredrecent if it had been performed during the year preceding theinterview; for the Pap test and proctosigmoidoscopy, within thepreceding 3 years. Data about CBE and mammography are presentedfor women age equal to or more than 40 years; for DRE, FOBT, andproctosigmoidoscopy, persons age equal to or more than 40 years,and for the Pap test, women age equal to or more than 18 yearswith an intact uterus.

From 1987 to 1992, the overall percentage of women age equal toor more than 18 years who re-ported having had a recent Pap testremained stable (Table 1). The percentage increased slightly forHispanic women, and remained low for women aged equal to or morethan 70 years.

The increase in the percentage of women ever tested was greaterfor women aged equal to or more than 50 years (85% to 89%) thanwomen aged equal to or more than 50 years (90% to 92%), and forblack (88% to 92%) and Hispanic women (75% to 83%) than whitewomen (91% to 92%).

During this period, the percentage of respondents who reportedrecent mammography increased at least twofold for women in everyage and racial/ethnic group. The greatest increases were for blackand Hispanic women; as a consequence, in 1992, screening rateswere similar for white, black, and Hispanic women. However, womenage equal to or more than 70 years in 1992 remained less likelyto have had a recent screening and to have ever been tested thanwomen age less than 70 years. From 1987 to 1992, the percentageof respondents who reported having had a recent CBE also increased;in 1992, at least 75% of women in each age group reported everhaving the test.

From 1987 to 1992, the percentage of respondents who reportedever having had a DRE increased from 49% to 54% for men and from51% to 54% for women. Although increases were greater for menthan women, rates for recent DRE were lower for men than women(22% vs 21% in 1992). Rates of recent FOBT remained stable; however,the rate for black men increased more than twofold, from 7% to15%. The overall percentages of respondents who reported everhaving had proctosigmoidoscopy increased for men (24% to 30%)and for women (21% to 26%), and the percentage screened recentlywas higher for men than women in both 1987 and 1992 (7% and 11%,respectively, vs 5% and 7%, respectively).

Editorial Note From the CDC

The analysis described in this report estimates use of cancerscreening tests based on a representative sample of the US population,and four of these tests have been targeted as national healthobjectives for the year 2000 (objectives 16.11-16.14). Althoughthe findings indicate an increase in the recent use of all cancerscreening tests (except the Pap test) from 1987 to 1992, percentagesare substantially lower than the national objectives. For example,one objective is to increase the rate of mammography among womenage equal to or more than 50 years to 60% every 2 years and amongwomen age equal to or more than 40 years to 80% ever (objective16.11). Based on this survey, the rate of recent mammography amongwomen age equal to or more than 50 years was 44% in 1992 and everhaving had mammography was 70% for women age equal to or morethan 40 years.

The differences in the screening rates and the national healthobjectives may, in part, reflect for respondents a lack of (1)health insurance coverage, (2) a primary-care physician, or (3)clear communication between physicians and patients about theimportance of routine screening. For example, the lower rate ofmammography use by women age equal to or more than 50 years (whoare at greatest risk for breast cancer) may reflect the findingthat these women are less likely to visit gynecologists, and ofall physician specialists, gynecologists are most likely to recommendmammograms. In addition, for women with low incomes, the mammographyobjectives are unlikely to be met because facilities that performmammography may not accept women without a referral from a primary-carephysician, and a disproportionate number of women with low incomesdo not have a regular health-care provider. To promote mammographyscreening among older women, since 1990, Medicare has reimbursedthe cost of biennial mammograms. Although the reimbursement feeis substantially less than the median price of mammograms in theUS, the fee is feasible if mammograms are delivered using moreefficient methods and established mass-production techniques.

In the United States, managed care and the increased use of healthmaintenance organizations (HMOS) are likely to increase the useof all preventive-care services (including screening examinations),particularly if primary-care physicians are encouraged to screenpatients routinely and recommend screening tests they currentlydo not perform. In addition, however, the importance of some screeningexaminations, such as the Pap test, may need to be emphasizedregularly in public health messages.

Reported by: N. Breen, PhD, L. Kessler , PhD, Applied ResearchBr., NCI, NIH, Div.of Cancer Prevention and Control, NationalCenter for Cronic Disease Prevention and Health Promotion; NationalCenter for Health Statistics, CDC.

Adopted from Morbidity and Mortality Weekly Report, vol 45,no. 3, 1995

Articles in this issue

Trends in Cancer Screening-United States, 1987 and 1992
Economic Savings and Costs of Periodic Mammographic Screening in the Workplace
Book Review: Dr. Susan Love's Breast Book, 2nd Edition
Trends in Smoking Initiation Among Adolescents and Young Adults-United States, 1980-1989
Pilot Study Points to Possibly Improved NSCLC Survival With Simultaneous Chemo/RT
DaunoXome Shows Promise as Breast Cancer Treatment
New Agent Blocks HIV Integrase, Another Target for Anti-AIDS Therapy
Topotecan Demonstrates Significant Activity in Small-Cell Lung Cancer
Xerostomia as a Complication of Cancer Treatment
Irinotecan Shown to Be Effective Against Colorectal Cancer
Talk More, Test Less, Panel Urges Health Providers
Docetaxel Said to Be Highly Effective and and Well Tolerated in Advanced Head and Neck cancer.
Trial of Topotecan as First - Line Treatment for Ovarian Cancer Announced
Isolation of New Transmissible Herpesvirus Suggests Additional Therapeutic Approaches for KS
Does Neck Stage Predict Local Control After Irradiation for Head and Neck Cancer?
Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content
Advertisement

Data from DeLLphi-304 support the use of tarlatamab as a standard of care for all patients with second-line small cell lung cancer.

Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups

Russ Conroy
October 18th 2025
Article

Data from DeLLphi-304 support the use of tarlatamab as a standard of care for all patients with second-line small cell lung cancer.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Novel Agent Meets End Points in COMPETE Trial for GEP-NETs

Novel Agent Meets End Points in COMPETE Trial for GEP-NETs

Paige Britt
October 18th 2025
Article

ITM-11 showed superior PFS and ORR compared with everolimus in patients with gastroenteropancreatic neuroendocrine tumors.


Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.


Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC

Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC

Gina Mauro
October 18th 2025
Article

Tarlatamab plus chemo/IO showed a 71% objective response rate and promising safety for patients with ES-SCLC in the DeLLphi-303 study.


Giredestrant plus everolimus doubled the ORR and prolonged the DOR in patients with ER-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor.

Giredestrant Combo Improves Efficacy vs SOC in ER+, HER2- Breast Cancer

Silas Inman
October 18th 2025
Article

Giredestrant plus everolimus doubled the ORR and prolonged the DOR in patients with ER-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor.

Related Content
Advertisement

Data from DeLLphi-304 support the use of tarlatamab as a standard of care for all patients with second-line small cell lung cancer.

Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups

Russ Conroy
October 18th 2025
Article

Data from DeLLphi-304 support the use of tarlatamab as a standard of care for all patients with second-line small cell lung cancer.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Novel Agent Meets End Points in COMPETE Trial for GEP-NETs

Novel Agent Meets End Points in COMPETE Trial for GEP-NETs

Paige Britt
October 18th 2025
Article

ITM-11 showed superior PFS and ORR compared with everolimus in patients with gastroenteropancreatic neuroendocrine tumors.


Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.


Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC

Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC

Gina Mauro
October 18th 2025
Article

Tarlatamab plus chemo/IO showed a 71% objective response rate and promising safety for patients with ES-SCLC in the DeLLphi-303 study.


Giredestrant plus everolimus doubled the ORR and prolonged the DOR in patients with ER-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor.

Giredestrant Combo Improves Efficacy vs SOC in ER+, HER2- Breast Cancer

Silas Inman
October 18th 2025
Article

Giredestrant plus everolimus doubled the ORR and prolonged the DOR in patients with ER-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.